Introduction
The Ras-signaling pathway has attracted considerable attention because of its important role in carcinogenesis. Mutations in the Ras oncogene have been found in approximately 30% of all human cancers (Reddy et al., 1982; Bos, 1989) . The Ras superfamily of small GTP-binding proteins plays a pivotal role in modulating various intracellular signal transduction pathways governing cell growth and dierentiation, apoptosis, membrane tracking and transcriptional regulation (Campbell et al., 1998; Shields et al., 2000; Bar-Sagi and Hall, 2000; Crespo and Leon, 2000; Adjei, 2001; Bar-Sagi, 2001 ). The Ras GTPases are located at the inner surface of the plasma membrane. In response to external stimuli, they switch from an inactive GDP-bound state to an active GTP-bound state, a conformational change that is catalyzed by a family of guanine nucleotide exchange factors (or GEFs) (Bar-Sagi, 2001 ).
In the GTP-bound conformation, Ras GTPases are able to interact with a series of downstream target proteins (also called Ras eectors) and promote cellular responses in a signaling cascade fashion (Marshall, 1996; Wittinghofer and Nassar, 1996; Katz and McCormick, 1997) . The interaction is mostly at the level of two discrete segments of Ras, termed switch I (or eector domain loop, residues 32 ± 38) and switch II (residues 60 ± 72), which exhibit a signi®cant GTP-induced allosteric change (Marshall, 1996; Bos, 1998; Campbell et al., 1998) . Several Ras eectors including the serine-threonine kinase Raf-1, phosphoinositide 3'-kinase (PI3-K), AF-6, RalGDS and Nore1 (Campbell et al., 1998; Vavvas et al., 1998) can be classi®ed based on sequence homology within a domain termed the Ras association (RA) domain (Ponting and Benjamin, 1996) .
Recently, we have cloned and characterized a human Ras eector homologue, RASSF1 (Dammann et al., 2000) . This gene maps on the short arm of chromosome 3 (exactly on 3p21.3), within a critical 120 kb region, often involved in loss of heterozygosity (LOH) and homozygous deletion events during lung and breast tumorigenesis (Sekido et al., 1998; Wistuba et al., 2000) . Three transcripts, A, B and C, derived from alternative splicing and dierent promoter usage, were identi®ed (Dammann et al., 2000; Burbee et al., 2001 ; see also Figure 1 ). The two major transcripts, RASSF1A and RASSF1C, were expressed in a wide variety of normal tissues. Transcript A was missing in almost all small-cell lung cancers (SCLC) analysed and in several other cancer cell lines (Dammann et al., 2000 (Dammann et al., , 2001a . Loss of expression of the splice variant RASSF1A in various tumors has been correlated with hypermethylation of its CpG island promoter (Dammann et al., 2000; Agathanggelou et al., 2001; Burbee et al., 2001; Dammann et al., 2001a,b; Lo et al., 2001; Lee et al., 2001; Yoon et al., 2001; Dreijerink et al., 2001) . Reexpression of RASSF1A in lung cancer cells was shown to reduce colony formation, to suppress anchorageindependent growth, and to inhibit tumor formation in nude mice (Dammann et al., 2000; Burbee et al., 2001) . These characteristics all together suggest a potential role of RASSF1A as a tumor suppressor gene in 3p21.3.
RASSF1A has a predicted RAS association domain at the C-terminus. The carboxy terminus of the translated nucleotide sequence shows high homology (55% identity) to the mouse Ras eector protein Nore1 and to the homologous rat protein Maxp1 (Dammann et al., 2000) . Nore1 interacts with Ras in a GTPdependent manner and has been shown to associate with Ras in vivo following receptor activation (Vavvas et al., 1998) .
Here, we have identi®ed two alternative splice forms of the human homologue of Nore1 and a third member of this family, which we have named RASSF3.
Results and Discussion
In order to identify new potential signaling intermediaries that interact with Ras-GTP, we performed BLAST searches using the predicted amino-acid sequence of the RASSF1A Ras association domain as the query. Several mouse and human EST clones were identi®ed by homology search and fully sequenced. In particular, we focused on two EST clones (Genbank accession numbers BE308695 and AA573427) that appeared to contain a mouse and a human homologue of the RASSF1 gene. We designated the two sequences RASSF3 and Rassf3 (approved by the human gene nomenclature committee; Genbank accession number: AF332864), for the human and mouse genes, respectively. These clones are clearly dierent from a previously identi®ed RASSF2 gene (Genbank accession number: XM-009569), which shares a much lower homology (29% identity) with RASSF1 (Genbank accession number: AF132675). The mouse Rassf3 clone contained the full-length cDNA with an open reading frame of 232 amino acids corresponding to a protein of 26.7 kDa. No further information is currently available in public databases regarding the genomic mouse Rassf3 locus. The human RASSF3 cDNA clone contained a 3' truncated cDNA sequence. The full-length sequence of human RASSF3 was deduced by homology of genomic sequences to the mouse gene, and it was assigned to human chromosome 12q14.1 (Figure 1 ). The RASSF3 gene contains ®ve exons and encodes a 247 amino acid protein with a predicted molecular mass of 28.6 kDa. The last four exons encode a consensus Ras association (RalGDS/ AF-6) domain with a 44% identity (59% homology) to the C-terminus of RASSF1 (both A and C isoforms) and 46% identity to the mouse Nore1 protein (Figures  2 and 3) . The protein sequence translated from the ®rst exon of RASSF3 has no similarity to Nore1 (data not shown) and RASSF1A ( Figure 3 ) but shares high homology with the translated sequence of the ®rst exon of RASSF1C (Figure 3) .
To investigate the expression of RASSF3, we performed a detailed Northern blot analysis by using human multiple tissue blots ( Figure 4 ). When a probe speci®c for the RASSF3 exon 1 was used for hybridization, a *3.8 kb-long band was observed in all normal tissues and human cancer cell lines analysed. In three cancer cell lines (melanoma G361, promyelocytic leukemia HL-60, and myelogenous leukemia K-562) shorter transcripts were also observed. In addition to the level of homology and the similar genomic organization (Figures 1 and 3 ), RASSF3 is expressed ubiquitously, similar as the RASSF1C variant. The homology to RASSF1 suggested that RASSF3 also could exist in various isoforms, perhaps as a common characteristic of several RA domain family members. To identify possible alternative transcripts, we used a probe speci®c for exon 3, in the core of the RA domain. Besides the ubiquitous 3.8 kb band, no alternative and/or additional signals were detected on Northern blots (Figure 4 ). Various attempts performed using 5' RACE (5'-rapid ampli®cation of cDNA ends) ampli®cation also failed to identify alternative RASSF3 transcripts (data not shown). With the exception of one mouse EST clone (Genbank accession number BB662258), no other RASSF3 splice variants have so far been identi®ed by EST homology search. This cDNA clone is homologous to the mouse Rassf3 gene but contains an apparently dierent ®rst exon, which has no homology to any other gene. Searches in the Celera mouse database suggest that this variant exon contains sequences between exon 1 and exon 2 of Rassf3.
In order to gain further information about the RASSF3 gene, we screened a Human Universal cDNA Library (HUCL library from Stratagene) using probes speci®c for RASSF3 exon 1 and exon 3. Of the eight clones identi®ed, only one appeared to contain a consensus Ras association domain. This clone showed (GenBank  AF332864) , human RASSF3 (AA573427 EST clone and predicted amino acid sequence from chromosome 12), human RASSF1C (Genbank AF132676), human RASSF1A (GenBank AF132675), human NORE1A (EST clone BE275987 and RT ± PCR sequence) and human NORE1B (GenBank: AF445801). Alignments were generated using the ClustalW algorithm (Thompson et al., 1994) , manually edited to maintain optimal overlapping, and displayed using the BOXSHADE program (http://www.ch.embnet.org./ software/BOX form.html). Identical and similar amino acids are boxed in black and gray, respectively 61% homology, at the amino acid level, to the human RASSF3 gene. A close match (94% homology) to the mouse Nore1 protein was observed, suggesting that we had cloned the human homologue of Nore1, NORE1. By homology search with the cDNA clone, we also identi®ed a new EST clone (Genbank accession number: BE275987) identical to NORE1 except for sequences in the 5' end. The gene derived from the fully sequenced EST clone BE275987 was named NORE1A. The human NORE1 clone isolated from the Stratagene library was named NORE1B. The two cDNA clones dier in their 5' terminus.
The human NORE1 gene is located on 1q32.1, and a detailed map is illustrated in Figure 1 . Very similarly to RASSF1 (Dammann et al., 2000; Burbee et al., 2001) , NORE1 exists in at least two isoforms, as a result of alternative splicing and dierential promoter usage. Both isoforms share a highly conserved Ras association (RalDDS/AF-6) (RA) domain (Ponting and Benjamin, 1996) , encoded by exons 3 through 6. NORE1A contains two additional 5' exons, designated as exon 1a and exon 2a while NORE1B starts from an alternative exon 2b, located at least 48 kb downstream of exon 1a (Figure 1) . The NORE1A cDNA clone + RNA from human cancer cell lines and human multiple tissues were hybridized with speci®c single-stranded probes generated by linear PCR ampli®cation using appropriate antisense oligonucleotides. (a) RASSF1 Northern blot analysis. For hybridization, dierent probes speci®c for exons 2a and exon 2g were used. A probe speci®c for b-actin was included as a control. (b) RASSF3 Northern blot analysis. Dierent probes speci®c for exon 1 and exon 3 were used for hybridization. (c) NORE1 Northern blot analysis. Probes speci®c for exon 1a and exon 2b were used to determine the expression of alternative NORE1 transcripts. A probe speci®c for b-actin was included as a control (EST clone BE275987) consisted of 3510 nucleotides and is characterized by a CpG-rich island at the 5' end and a 2.3 kb long 3' untranslated region. It contains an ORF of 389 amino acids with a calculated MW of 43.9 kDa. The N-terminus (residues 121 ± 168) of NORE1A has homology to a cystein-rich diacyglycerol/phorbol ester binding domain, also known as the protein kinase C conserved region 1 (C1) domain (Newton, 1995) . It has been suggested that Ras interaction with the cystein-rich domain (CRD) may be required for the activation of downstream eectors of Ras signaling. In the case of Raf-1 serine-threonine kinase, the best studied Ras eector (Avruch et al., 2001) , interaction of Ras with the Raf-CRD has been shown to promote the activation of Raf-1 in vivo, in part by facilitating translocation from the cytoplasm to the plasma membrane (Clark et al., 1997) .
At the extreme C-terminus, the NORE1A clone deviated from the consensus amino acid sequence shared by the other members of the NORE1/RASSF1 family. Alignment of the DNA sequence of this human NORE1 cDNA with those of mouse Nore1 and rat Maxp1 indicated a deletion of 138 nts in the human clone, resulting in the replacement of 37 highly conserved carboxyterminal amino acids of mouse Nore1 by a novel 11 amino acid carboxyterminus (sequence SSWCIQIYLYY). This could be due to an alternative splicing event in exon 6; however to verify the existence of this variant, we obtained from NCI an aliquot of the mRNA used for construction of the original cDNA library (NIH-MGC-20), as well as the parental human melanoma cell line itself. The mRNA aliquot, as well as total RNA prepared from the cognate melanoma cell line, and from two unrelated human melanoma cell lines were subjected to RT ± PCR using two sets of oligonucleotide primers¯anking the putative deleted segment. Whereas the IMAGE cDNA clone predicts PCR fragments of 341 and 285 bp, the authentic mRNA and all RT ± PCR reactions gave identical fragments of 479 and 423 bp, corresponding in length to those predicted by the mouse Nore1 and rat Maxp1 sequences ( Figure 5 ). Direct sequencing of the human RT ± PCR fragments indicated that the human NORE1A and NORE1B carboxyterminal amino acid sequences are identical and homologous to those of the rodent polypeptides. We conclude that the alternative carboxyterminal sequence in EST clone BE275987, and in NCBI entries AAH07203, NP-113625, BC004270, and XP-051969, is in error. The apparent deletion of 138 bp probably re¯ects aberrant reverse transcription during construction of the cDNA library.
The other transcript (3.6 kb), NORE1B, uses an alternative transcription initiation area (exon 2b) located at least 24 kb downstream of exon 2a and is characterized by a canonical CpG island. Exon 2b has two hypothetical AUG initiation codons, preceded immediately upstream by an in frame stop codon, and encodes a 265 amino acid protein with a presumed MW of 30.5 kDa. The protein sequence translated from the exon 2b has no similarity to NORE1A or RASSF1A. Instead it displays high homology with RASSF1C and with both mouse and human RASSF3 (Figure 3 ). The nature of such a conserved sequence domain at the N-terminus of these proteins is unknown, but it might be related to a speci®c function of the shorter isoforms of this gene family. Interestingly, the N-terminus of RASSF3 shows some similarities with a short segment of the Ran-binding domain (RanBD). This domain stabilizes the GTPbound form of Ran (a Ras-like nuclear small GTPase involved in nucleocytoplasmatic transport) and is conserved in several Ran-binding proteins (Petersen et al., 2000) .
We also investigated the expression of NORE1A and NORE1B by Northern blot analysis (Figure 4) . When a probe from exon 2b (speci®c for NORE1B) was used for hybridization, a single band of approximately 3.5 ± 4.0 kb was observed. Although at variable intensity, the signal was present in all the normal tissues analysed, but it was absent or down-regulated in HeLa S3 cells, in lung carcinoma A549, and in melanoma G361 (Figure 4) . Figure 5 RT ± PCR of NORE1A using RNA isolated from human melanoma cell lines. (a) RT ± PCR using RNA prepared from the human melanoma cell line from which the NIH_MGC_20 library was made (lanes 1, 2) or from the human melanoma cell line M14 (lanes 3, 4). Primer set 1 was used in lanes 1 and 3. Primer set 2 was used in lanes 2 and 4. (b) RT ± PCR using mRNA from the human melanoma cell line parent to the NIH_MGC_20 cDNA library. The RNA samples were prepared at this laboratory (lanes 1, 2) or at NCI (lanes 3, 4) . The latter is the mRNA used for construction of the NIH_MGC_20 cDNA library. Primer set 1 was used in lanes 1 and 3. Primer set 2 was used in lanes 2 and 4 Using a probe from exon 1a (speci®c for NORE1A) a more complex expression pattern was detected. At least two to three distinct signals migrating between 4 and 7.5 kb were seen. We do not know the exact origin of these bands (two major forms and one minor one seen only in spleen, prostate and pancreas). Since the NORE1B probe shows only one band, alternative splicing involving exons 3 ± 6, which encode the Ras association domain, is unlikely. We considered the possibility of alternative splicing or termination in the long 3' untranslated region. However, variants have so far not been identi®ed by library screening, analysis of EST clones, or by RT ± PCR.
Most of the normal tissues analysed showed expression of the shorter 4.0 kb transcript. However, several cancer cell lines such as promyelocytic leukemia HL-60, lymphoblastic leukemia MOLT-4, Burkitt's lymphoma Raji, lung carcinoma A549 and melanoma G361 expressed very low levels of this NORE1A transcript. Colorectal adenocarcinoma SW80, myelogenous leukemia K562 and HeLa cells showed transcript levels comparable to those in normal tissues.
A large number of reports in the literature document the role of methylation in gene inactivation and tumorigenesis (Baylin et al., 1998; Jones and Laird, 1999; Baylin and Herman, 2000) . That methylation plays a key role in the silencing of RASSF1A in a large variety of tumors has been recently demonstrated (Dammann et al., 2000 (Dammann et al., , 2001a Agathanggelou et al., 2001; Burbee et al., 2001; Lo et al., 2001; Lee et al., 2001) .
To determine if NORE1A and NORE1B are epigenetically inactivated in cancer cell lines and tissues, we checked the methylation status of the CpG islands at which the two transcripts initiate. A restriction analysis of PCR ampli®ed bisulphitemodi®ed DNA from normal and cancer tissues was performed as previously described (Dammann et al., 2001a,b) . We focused on three tumor types for which the NORE1B transcript was not expressed in the respective cancer cell lines: lung cancer, melanoma, and cervical carcinoma. The analysed 373 bp region of the NORE1B promoter contains 43 CpG sequences. The methylated fragment will contain two TaqI sites (TCGA) and digestion will result in bands of 233, 77 and 63 bp, respectively. The 293 bp NORE1A methylated promoter fragment will contain only one TaqI site and digested products will be 169 and 124 bp long. We screened a total of 49 melanomas, 40 cervical carcinomas, 14 lung cancer cell lines and 14 lung primary tumors with the respective matching normal tissues, but no evidence for methylation was found in the NORE1B CpG island. Only HeLa cells and one lung primary tumor showed at least 50% methylation, as shown by TaqI digestion of the 373 bp fragment (Figure 6 ). Methylation does not occur either in the NORE1A CpG island following restriction analysis of 10 lung cancer cell lines and 12 melanomas (data not shown). Some partial methylation was detected only in HeLa cells. Since mechanisms other than promoter methylation can be responsible for gene silencing, such as somatic point mutation, we next performed a detailed mutational analysis of NORE1A and NORE1B cDNAs. We found only a few silent mutations (probably rare polymorphisms) in the nine melanomas and 20 lung tumors analysed. Interestingly, common polymorphisms exist at two potential Sp1 sites within the NORE1B promoter (at position 7208 and 7261, respectively; relative to the ATG codon), with possible implications for gene regulation. For completeness, we also sequenced the cDNA of RASSF3 in 10 breast tumors and 17 lung tumors. As in the case of NORE1B, sequence changes were detected mostly in the regulatory region at a potential Sp1 site (at position 726 relative to the translation start site, C to T). No mutations were found in the coding sequences except for a CAA (Gln36) to CAG (Gln36) polymorphism in 30% of the breast samples analysed and a rare CGT (Arg241) to CAT (His241) polymorphism found in only one sample.
Chromosomal sequences containing both NORE1 (1q32.1) and RASSF3 (12q14.1) are not known to be lost frequently in tumors. Ampli®cation of 1q32 has been described more commonly (Ried et al., 1995; Almeida et al., 1998; Kros et al., 1999) . It remains to be determined if the NORE1 gene is involved in this ampli®cation.
Here, we report the isolation of two human homologues of the tumor suppressor gene RASSF1A, RASSF3 and NORE1. Because of their sequence homology with a conserved Ras association domain, RASSF3 and NORE1 can be classi®ed as potential Ras eectors, but their direct involvement and exact function in Ras-like signaling pathways remains to be elucidated. It has been emphasized that not all the proteins containing a consensus RA domain may interact with Ras GTPases in vitro/vivo but the signi®cance of this remains unclear (Wittinghofer and Herrmann, 1995) . The homology of the RASSF1A gene with the mammalian Ras eector Nore1 suggests that the gene product may function in signal transduction pathways involving Ras-like proteins. In a recent study, Vos et al. (2000) have shown that RASSF1C binds Ras in a GTP-dependent manner and that its overexpression induces apoptosis (Vos et al., 2000) . The pro-apoptotic eect of RASSF1C was enhanced by activated Ras and inhibited by dominant negative Ras. However, our recent data indicate that the pro-apoptotic eect of RASSF1 may require heterodimerization with NORE1 and that RASSF1 itself binds to Ras only very weakly (Ortiz-Vega et al., 2002) . In addition, there is evidence for an association of both NORE1 and RASSF1 with the pro-apoptotic kinase MST1, and that this interaction is involved in apoptosis induced by activated Ras (KiRasG12V) .
The existence of several isoforms of Ras eectors, here shown to be typical of two closely related RA family members, may suggest a speci®c role of the dierent variants in the interaction and/or signal transmission of Ras or Ras-like proteins.
Materials and methods

Library screening and gene cloning
The EST clones were obtained from Incyte Genomics Inc. (Palo Alto, CA, USA). They were sequenced on both strands using an ABI automated DNA sequences. A Human Universal cDNA Library (HUCL library) was obtained from Stratagene (La Jolla, CA, USA). This library was used to isolate the NORE1B gene. The library was screened using PCR-generated probes speci®c for RASSF3 exon 1 and exon 3, respectively. Positive clones were obtained and sequenced in their entirety.
RT ± PCR
Total RNA was extracted using the Trizol Reagent and its recommended protocol (Gibco ± BRL). RT ± PCR was performed using the SuperScript One-Step RT ± PCR with Platinum Taq Kit (Invitrogen). A common antisense primer (5'-GCT TGC AGA TCG AGA GAG GAC-3') was used in combination with two dierent sense primers (5'-GAC ACG GAG GTC CTC AGC TTT-3' and 5'-CGA TGC CTT CTC CAT CCC TGA-3'). First strand synthesis was carried out at 508C for 30 min. After denaturing at 948C for 2 min, the reactions underwent 40 cycles of 948C, 20 s for denaturing, 558C, 30 s for primer annealing and 728C, 40 s for DNA synthesis.
Northern blots
Human multiple tissue Northern blots were obtained from Clontech (Palo Alto, CA, USA). They were hybridized with probes speci®c for RASSF1, exons 1a or 2g, RASSF3, exon 1 or 3, NORE1A, exon 1a, NORE1B, exon 2b, or b-actin.
DNA methylation analysis
Melanoma and lung cancer cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). Primary frozen tumor material from lung cancer and melanoma cases was obtained from the Anatomic Pathology Department of the City of Hope Medical Center. DNA methylation in the CpG island region of NORE1B was analysed by restriction enzyme analysis of PCR products obtained from bisulphite converted DNA (Xiong and Laird, 1997) . One mg of genomic DNA was denatured in 0.3 M sodium hydroxide for 15 min at 378C. Cytosines were sulfonated in 3.12 M sodium bisulphite (Sigma; St. Louis, MO, USA) and 5 mM hydroquinone (Sigma) in a thermocycler for 16 h at 558C. The DNA samples were desalted through columns, desulfonated in 0.3 M sodium hydroxide and precipitated. DNA sequences were ampli®ed by mixing 50 ng of bisulphite treated DNA with primers MU-554 (5'-ATGATTTGTAGTTTTTTGAGTTTATTTGTT) and ML+26 (5'-TCCAAACTACAATACCCACTACTCATAC-TA) in 25 ml reaction buer containing 200 mM of each Figure 6 Methylation analysis of NORE1B by restriction digestion with TaqI. PCR products (*30 ng) from bisul®te-treated DNA obtained from dierent cell lines, primary tumors (T), and normal samples (N) were digested (+) or mock-digested (7) with 10 units of TaqI. The sizes of molecular weight markers (M) are shown on the left in bp dNTP and Taq polymerase (Roche Diagnostics Corp.; Indianapolis, IN, USA) and incubating at 958C for 3 min, and then at 958C for 30 s, 558C for 30 s and 738C for 40 s, for 25 cycles. A nested PCR was performed using one ®fth of the initially ampli®ed products and the internal primers MU-454 (5'-AGGAATTTTGTAGAGGAAGTGGTTT) and ML-82 (5'-AAAAAAAATAAACACCCCTCCC) with similar conditions as described for the preceding PCR ampli®ca-tion, but for 30 cycles. The PCR products were puri®ed using QIAquick PCR puri®cation kits (Qiagen, Valencia, CA, USA). For the restriction enzyme analysis of PCR products from bisulphite-treated DNA, 30 ng of the PCR products were digested with 10 units of TaqI (New England Biolabs; Beverly, MA, USA) according to conditions speci®ed by the manufacturer of the enzyme and analysed on a 2.2% TBE agarose gel.
